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Bovine respiratory diseases are considered to be the major problem 
confronting the beef industry today. It has been estimated that the 
economic loss due to respiratory disease costs $10 to $20 for every calf 
in the feedlot (15). 
The bovine respiratory disease complex (BRDC), as shown below (14 , 
16,47), lists what are thought to be the major factors and organisms in-
valved in the BRDC. These agents may act alone or in combination. 
Stress + Viral infection + Bacteria 1 infection = BRDC 
Heat Infectious bovine Hemophilus 
rhinotracheitis 
Cold Para i nfl uenza-3 Pasteurella 
Chilling Bovine viral diarrhea Mycoplasmas 
Dampness Malignant catarrhal Chlamydiae 
fever 






Fright Other viruses? 
Several vaccines and bacterins are available and have been in use for 
some time. The most effective vaccines are the modified live virus vac-
cines but there are risks involved that may be more costly than the bene-
fits. Attenuated vaccines administered to pregnant animals have been in-
criminated in abortions, fetal deformation and pathological lesions (22). 
Some animals may be highly susceptible to the attenuated virus and there 
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is the potential for reversion to the virulent virus. The control of BRDC 
is seldom accomplished by irrvnunization due to the plurality of the agents 
involved. 
Since the discovery of interferon {17), many researchers have hoped 
that it would be the answer to the control of viral diseases. Interferon 
can be induced by a number of viruses, synthetic nucleic acids and other 
synthetic anionic polymers. Because of the inherent danger of using live 
virus as inducers, a search for suitable synthetic inducers was imple-
mented. 
Among the polyanion inducers, pyran, a divinyl ether-malic anhydride 
copolymer (DIVEMA), has been shown to protect mice against several viruses 
(6,7,25,26,28,30,33,37) and some bacteria (27,35,41 ) . In addition to 
interferon stimulation DIVEMA has been shown to produce a marked biphasic 
response in the functional activity of the reticuloendothelial system 
(RES) (32,39), enhance the humoral antibody response (3,4), alter drug 
metabolism (40), and retard the growth of induced tumor cells (18). 
Although a number of successes with DIVEMA have been reported in 
laboratory animal systems, little work has been done in the applied field. 
DIVEMA, because of its broad-spectrum prophylaxis, appears to be a good 
candidate for further testing against the complexity of etiological agents 
of the BRDC. 
This preliminary investigation evaluated the antimicrobial activity 
of DIVEMA in calves against two micro-organisms of the BRDC. 
The first experiment was designed to test DIVEMA's ability to enhance 
the irrmune response to one or two doses of inactivated Infectious Bovine 
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Rhinotracheitis ( IBR) vaccine . Also information was obtained on the 
effect of DIVEMA given alone 48 hours before challenge with IBR virus. 
The second experiment tested the antibacterial effects of DIVEMA in 
calves infected with Hemoph i lus somnus. 
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LITERATURE REVIEW 
Historically the anticoagulant effects of heparin in relation to its 
calcium binding was studied to evaluate its potential in retarding tumor 
growth . The use of anticoagulents or 1ipolytic agents produced alopecia, 
ulceration of the mucosa of the gastrointestinal tract and osteoporosis 
leading to pathological fractures {36). 
Regelson 1 s group then began a systematic search for heparnoids that 
have tumor inhibiting properties without side effects. They evaluated 
synthetic polymers derived from ethylene maleic anhydride. Two agents 
were selected for clinical testing. One of these agents was the poly-
anionic pyran copolymer of carboxylic diviny1 ether maleic anhydride also 
designated MA/DVE (26), DVE/MA (4), and DIVEMA1. 
Antiviral Activity 
Regelson and Foltyn (38) reported that the synthetic polycarboxylate 
pyran produced an average of 65% inhibition of Friend Leukemia virus (FLV) 
induced splenomegaly in mice when gi ven intraperitoneally (IP) daily for 
6 days beginning 24 hours after viral infection. When they gave pyran 6 
days prior to FLV inoculation there was a 78% inhibition of splenomegaly. 
Regression of establi shed FLV tumors was not seen . 
In continued studies with FLV Regelson (37) observed that pyrans were 
capable of antiviral activity as well as antitumor activity. This was 
consistent with the findings of other workers that had shown that 
1Hercu1es Inc., Wilmington, Del. 
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polyanions possessed both antitumor activity and antiviral activity . 
Regelson attempted to determine a mechanism that would explain the inhi-
bition obtained with pyran admi nistration following FLV infection . Two 
phenomena were observed; one was the appearance of interferon in the serum 
of mice inoculated with pyran alone and the other was direct in vitro 
neutra lization of FLV by pyran. 
Merigan (26) became interested in the synthetic copolymers of maleic 
acid anhydride after Regelson suggested the antiviral activity might be 
due to interferon. Merigan confirmed Regelson's findings and character-
ized the antiviral activity, identified it as interferon and determined 
structural requirements of the copolymers for inducing interferon. 
The required structure for the polyanions was found to be a saturated 
linear polymer with carboxylate groups on two out of every four carbons in 
either alternate or adjacent positions. Pyran copolymers were found to be 
the most potent inducers of interferon. Pyran is a copolymer of maleic 
anhydride and divinyl ether with a high density of carboxylate groups and 
a six-membered ring structure built into the polymeric backbone. Pyran 
has been synthesized in a variety of molecular weights ranging from 17,000 
to 540,000. A molecular weight of 17,000 was required for activity while 
high molecular weight polymers were found to be less active. High molec-
ular weight pyrans were very toxic in clinical trials in man (37) . 
The appearance of interferon may occur through two mechanisms. One 
involves the release of preformed interferon and the other the synthesis 










Newcastle Disease virus (NOV) and statolon (a fungal virus preparation) 
activate both mechanisms while non-viral stimulators, polynucleotides and 
endotoxin, only release preformed interferon. 
Pyran resembles statolon in that the interferon it induces is of 
70,000 MW (25). Pyran also resembles statolon in production of long last-
ing protection. Schmidt et al . (45) compared the duration of protection 
of mice from encephalomyocarditis virus challenge. The longest signifi-
cant protection provided by each inducer was endotoxin, 5 days; poly I/C, 
30 days and statolon or pyran, 55 days. Peak levels of interferonappeared 
several hours (24-48) after administration of pyran (26) or statolon (50), 
whereas peak levels stimulated by endotoxi n (50) or poly I/C (9) were seen 
at 2-3 hours. 
Pyran differs from statolon and NOV in ability to stimulate inter-
feron in vitro. Statolon and other viral inducers are able to induce 
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interferon in a variety of cell types whereas pyran only induced inter-
feron in the less fastidious cells such as mouse peritoneal macrophages 
and human fibroblasts (11 ) . .!.!!. vivo studies (13) in mice show the spleen 
to be a major source of interferon synthesis. If the spleen has been re-
moved there is a marked reduction (87%) in interferon titers following 
NOV. When pyran was injected 14 days after spleen removal there was a 
62% reduction in interferon levels; however, if pyran was injected 30 days 
after spleen removal there was no reduction in interferon titers. Pyran 
also differed from the viral inducers i n that interferon production in-
duced by pyran was significantly more resistant to Actinomycin D (12). 
Pearson et al. (33) extended studies of the antiviral effects of 
pyran in mice to Rauscher leukemia virus (RLV), murine sarcoma virus 
(Moloney Plasma Variant) MSV (MPV) and a first generation transplant in-
duced by the Moloney leukemia virus (MLV-T), as well as FLV . Four param-
eters were used to measure pyran's effectiveness: viral-induced spleen 
foci (SF), splenomegaly (Sp), survival time (ST) and virus reduction. The 
model systems showed a marked decrease in SF, Sp, and viral replication, 
and an increase in ST following pyran administration. Surviving mice 
appeared to be free of the disease. Interferon was hypothesized to be the 
mechanism of action against the viruses. 
In all of the studies that reported prolonged viral protection, the 
model systems used were intraperitoneal injections of mice with both pyran 
and virus (26,28,29,37). Declercq and Merigan (7) explored other routes 
of injection of pyran and virus. Pyran was administered either intra-
nasally or intraperitoneally to mice and the animals were challenged 
intranasally with vesicular stomatitis virus (VSV). Either route of 
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treatment significantl y protected against virus infection; however , t he 
long term protection seen in other studies was not obtained . Intranasal 
instillation of pyran was only effective if applied 3-4 hours before in-
fection. Intraperitoneal injection of pyran provided protection for only 
a few days . The findings suggested protection was due to interferon 
production. 
Richmond (42) conducted experiments in mice to test pyran's ability 
to protect against Foot-and-Mouth Disease virus (FMDV) . He found a bi-
phasic pattern of protection. Peak levels of resistance to infection were 
found at 4 hours, which was of short duration, and at 48-72 hours, gradu-
ally subsiding around the 7th or 8th day. Serum levels of interferon were 
demonstrated in the samples taken on days l and 2 after pyran administra-
tion. Richmond hypothesized that the protection seen at 4 hours was the 
release of preformed interferon and the protection seen 48-72 hours later 
was newly synthesized interferon . 
Richmond and Campbell (43) continued their experiments to see if 
they could determine a mechanism of protection afforded by pyran against 
FMDV infection . They had ruled out the possibility of direct neutraliza-
tion in a previous study (42). They examined the possibility that pyran 
affects the adsorption of FMDV onto susceptible cells. Virus adsorption 
was tested in various minced target organs from pyran treated mice and 
non-treated mice. They found that the pyran treated tissues adsorbed 
virus to the same degree as the non-treated tissues. It was noted, how-
ever, that the pyran treated tissues did not support.:!..!! vitro replication 
of the virus. It was not determined if the repressed multiplication was 
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due to interferon because protection had occurred beyond the time inter-
feron could be detected in the tissues. 
In addition to interferon production pyran is capable of direct 
neutralization of virus. Regelson (37) reported that when FLV was incu-
bated with pyran at room temperature for 30 minutes prior to inoculation 
there was little or no infective virus remaining. Other researchers con-
firmed this direct polyelectrolyte interaction with Mengo virus, VSV, 
Semliki Forest virus, Echovirus 9, and Vaccinia (7,28). Richmond (42) 
found that preincubation of pyran and FMDV did not alter the infectivity 
of that virus. 
Since interferon has only been demonstrated in the serum and tissues 
for 7 days after pyran treatment and protection has been shown to last up 
to 2 months in mice against several viruses, mechanisms other than inter-
feron have been proposed for the antiviral activity of polyanions. 
Regelson (36) reviewed the work of others and hypothesized that polyanions 
may activate lipases and esterases which could in turn inactivate the 
lipid-containing viruses. Moreover, lipid fractions would stimulate the 
reticuloendothelial system (RES) . 
Billiau et al. (1) also proposed that stimulation of the RES cells is 
a logical hypothesis for the prolonged antiviral action of polycarboxyl-
ates. He poi~ts out that polycarboxylates have been shown to be ingested 
by macrophages and that these compounds are not readily biodegradable . He 
suggested that the RES cells are continually being 'activated' and this 
may result in increased uptake and destruction of virus. 
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Antibacterial Activity 
Antibacterial effects of known interferon inducers were investigated 
by Pindak (35). If pyran, statolon or endotoxin were given to mice 24 
hours before infection with Klebsiella pneumonia 80-100% of the mice sur-
vived the lethal challenge, whereas in the untreated controls the survival 
rate was 25%. The surviving mice were rechallenged 21 days later. The 
survival rate for all mice on rechallenge was nearly 100% indicating that 
the mice pretreated with interferon inducers were able to develop immunity 
of the same order as that produced in a natural infection. Mice chal-
lenged for the first time at 21 days following treatment with the inducers 
were no more resistant than the untreated controls. 
In a second investigation Pindak (34) used the same protocol as de-
scribed in the preceding paragraph except that on day 6 the survivors were 
inoculated with encephalomyocarditis virus (strain MM). The mice were 
protected from the virus indicating that the intervening bacterial chal-
lenge did not diminish the effects of the interferon inducers. 
Regelson and Munson (39) compared the effects of pyran and poly I/C 
in mice against bacterial (pneumoccocus) and fungal (Cryptococcus 
neuformans) infections. They found complete protection with both treat-
ments if the interferon inducers were given 2 days prec~ding the challenge. 
Remington and Merigan (41) were interested in determining if the long 
term resistance produced against viral challenge by pyran could also be 
produced against intracellular bacterial infections. They found that when 
pyran was administered to mice intraperitoneally 18 hours before Listeria 
monocytogenes challenge by the same route no resistance was conferred. In 
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fact the treated mice died earlier than the controls. However, further 
experiments showed that if Listeria was given during the period of 4 days 
to 2 months after pyran administration mortality was decreased. Remington 
and Merigan also noted that more protection was conferred if pyran was 
given subcutaneously. They presumed that this route lessened the toxicity 
that had been seen when pyran had been administered close to the bacterial 
challenge. Efforts to find a mechanism of action revealed that macro-
phages from pyran treated mice were resistant to challenge with listeria 
in vitro. They hypothesized that resistance to intracellular bacterial 
infection may be related to the inducer's ability to enhance cell mediated 
defense mechanisms against foreign antigens. 
Adjuvant disease in rats is believed to be a fonn of delayed hyper-
sensitivity to mycobacterial antigens in Freunds complete adjuvant. The 
first symptoms (polyarthritis, periostitis, and tendinitis) are apparent 
at 10- 14 days . When Kapusta and Mendelson (19) gave pyran during the 
period of 1 day before until 7 days after injection of adjuvant, the ex-
tent of the hypersensitive reactions was s ignificantly decreased. They 
proposed that pyran had induced an antiinflammatory or an antiimmune 
effect. 
Reticuloendothelial Stimulation 
A biphasic response in the phagocytic activity of the RES is pro-
duced by pyran . Regel son et al. (40) measured intravascular clearance of 
colloidal carbon and organ uptake of 1131 lipid emulsion and Cr51 sRBC in 
mice . The first 2 days following injection of pyran there was a marked 
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depression of phagocytic activity but at days 7 and 9 the activity was 
markedly stimulated . During the depressed phagocytic stage there was also 
a depression of hepatic and splenic uptake of the lipid emulsion and sRBC 
whereas in the lung and thymus there was an increased uptake of sRBC but 
no increase was noted for the lipid emulsion. During the stimulated 
phagocytic stage there was increased uptake of sRBC in the liver and 
spleen but lipid emulsion uptake was increased only in the spleen. The 
degree of depression or stimulation appeared to be dependent upon the test 
agent. SRBC showed a greater depression as well as greater stimulation of 
RES function. 
Munson et al. (32) found the primary immune response as measured by 
the Jerne plaque technique to be closely related to the biphasic response 
of phagocytic acti vity. During the depressed RES phase there was a delay 
in production of antibody-forming cells. When the antigenic stimulus was 
given during the enhanced RES phase the antibody response appeared to be 
due to an increase in the number of spleen cells responding rather than an 
increase in production of antibody by competent cells. 
Kapila et al . (18) noted that phagocytic activity was stimulated by 
pyran and applied this finding to studies in mice that had methylchol-
anthrene induced tumors. Mice were injected daily with pyran for 3 days 
and challenged with a suspension of tumor cells. Pyran delayed the onset 
of the tumors by 4 weeks but did not decrease the incidence of tumors. 
The average weight of the tumors was significantly reduced in the pyran 
treated mice . 
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Antibody Formation 
Since polynucleotides and endotoxin were known to stimulate antibody 
formation, Braun et al. (3) evaluated the effects of pyran on antibody-
forming cells in mice . Pyran was injected IP at the same time sRBC were 
injected intravenous l y (IV). Hemolysin-forming spleen cells were assayed 
by the Jerne plaque method. Pyran enhanced the early response to sRBC; 
however, by 72 hours there was no enhancement. Histological sections of 
mouse spleen showed that within 24 hours after injection of pyran the 
small cells of the germinal centers disappear and the spleen becomes 
filled with large pyroninophilic reticulum cells of the kind associated 
with enhanced phagocytosis . 
Campbell and Richmond (4) investigated the ability of pyran to en-
hance the irrrnune response to FMDV vaccine. Mice given vaccine and pyran 
simultaneously were significantly more resistant to challenge than those 
receiving the vaccine or pyran alone . Peak levels of resistance occurred 
at days 2 and 3, but began to wane at days 7 and 8. Neutralization tests 
were performed to determine if the greater resistance of mice given both 
pyran and vaccine was due to enhancement of antibody production. They 
found no significant differences in antibody levels in the mice given both 
the inducer and vaccine or the vaccine alone. 
Deleterious Effects 
Merigan and Regelson (29) reported that in patients given pyran for 
so lid tumor therapy, thrombocytopenia was a major side effect in all pa-
tients whose dosage was 8 mg per kg or higher. A few days after the drug 
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was discontinued platelet levels returned to normal and no serious hemor-
rhages occurred. The only other side effect seen in these patients was 
fever over 101 F which subsided within 48 hours after the drug was ad-
ministered. 
After an occurrence of a hemolytic-uremic-like syndrome in a patient 
undergoing treatment with pyran, Leavitt et al. (20) studied the effects 
of pyran on intravascular coagulation in three patients that were being 
treated with the copolymer. Within several hours after pyran administra-
tion patients exhibited a prolongation of the partial thromboplastin time 
and a rapid drop in factor V activity. This was consistent with in vitro 
studies with pyran added to normal plasma which produced prolongation of 
both partial thromboplastin time and thrombin time and decreased factor V. 
Leavitt and co-workers also reported that pyran administration consistent-
ly produced a fever and in most cases was accompanied by a morbiliform 
rash and leucocytosis. 
Munson and Regel son (31) observed that mice given pyran 24 hours 
before intravenous injection of endotoxin were more sensitive to t he 
lethal effects of the toxin. This sensitivity occurred during both the 
depressed and stimulated phases of RES activity. 
In an attempt to obtain protection of pigs against FMDV, McVicar 
et al. (23) gave the animals high doses of pyran. The pigs developed 
elevated temperatures, were extremely lethargic, had signs of abdominal 
pain and refused to eat . On the second day after pyran treatment the pig 
receiving the highest dose was found dead, A necropsy revealed a severe 
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peritonitis. The condition of the other pigs was so poor challenge with 
FMDV was not done. 
Pyran is taken up by the reticuloendothelial system and remains there 
for prolonged periods of time. This may be a therapeutic disadvantage. 
The effects of the prolonged presence of the copolymer in the RES are not 
known (36). 
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MATERIALS AND METHODS 
Experiment I 
DIV EMA 
Solutions of DIVEMA1 (XA146-85-2) were prepared in 0.15 M NaCl. 
Addition of 20% NaOH helped to speed dissolution . When the recommended 
pH of 7.2 was reached, adjustment to volume was made. The fina l concen-
tration of DIVEMA was 100 mg/ml. The DIVEMA solution was sterilized by 
filtration through 0.22 µ Nalgene disposable filter2 and refrigerated 
(4 C) until used. 
Ce 11 cultures 
Either Madin-Darby bovine kidney3 (MDBK) or Georgia bovine kidney4 
(GBK) cells were utilized for the cell work throughout this study. Cell 
cultures were grown in Dulbecco's modification of Eagles minimum essen-
tial medium (MEM) 5 supplemented with 10% fetal calf serum (FCS) 5 that 
had been heat inactivated at 56 C for 1 hour . The buffers used in 100 ml 
of medium were 3 ml of 7. 5% sodium bicarbonate and a combination of organ-
ic buffers 6 N,N'-bis(2-hydroxyethyl)-2-aminoethane sulfonic acid (BES), 
l Hercules, Inc., Wilmington, Del. 
2Nalgene Labware Division, Rochester, N. Y. 
3American Type Culture Collection 
4 R. F. Solarzano, University of Missouri, Columbia, Mo . 
5Grand Island Biological Corp., Grand Island, N. Y. 
6Nutritional Biochemical Corp., Cleveland, Ohio . 
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N-2-hydroxYethyl-piperazine-N-2-ethanesulfonic acid (HEPES), and N-2-
hydroxyethyl-piperazine propane sulfonic acid (HEPPS) in final concentra-
tion of 10, 15 , and lOmM, respectively (11). Antibiotics used in all 
media were penicillin G1 (100 I.U./ml) and streptomycin sulfate (100 mg/ 
ml). Cells were grown in 250 ml plastic flasks 2 at 37 C in the presence 
of 5% co2. 
Cells were subcultured as needed for viral work or at 4 or 5 day 
intervals to maintain cell viability. Cells to be subcultured were washed 
three times with 3 ml of Rinaldini enzyme solution (R-saline) (44). Two 
ml of a trypsin solution (0 . 1% trypsin3, 0.02% versene4, andR-saline) were 
dispensed to the cell surface and then removed after 2 minutes. Flasks 
were incubated at 37 C for a few minutes to loosen the cells completely. 
Cells were suspended in MEM and dispensed into new flasks or test pla tes. 
All tissue culture work was done under a positive pressure plexiglass 
hood . 
!BR vaccine 
The Cooper strain of !BR virus5 was propagated in GBK cells. Virus 
was freed from the cellular debris by centrifugation for 10 minutes at 
2,500 rpm. The virus had a titer of lo8·5 TCID50;ml and was concentrated 
1Eli Lilly and Co . , Phillipsburg, N. J . 
2Falcon Plastics, Oxnard, Calif. 
3Difco Laboratories, Detroit, Mich. 
4J. T. Baker Chemical Co., Phillipsburg, N. J. 
5veterinary Biologics Divi s ion U.S. D.A . , Ames, Ia . 
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one additional log through an Amicon ultrafiltration system1 Virus was 
checked for sterility, inactivated by a 1:1000 dilution of beta-proprio-
lactone and placed in a Wheaton vaccine bottle. The vaccine was kept at 
-70 C until used. 
Serum neutralization test 
Serum neutralization (SN) tests were performed in Linbro2 micro-titer 
tissue culture plates. Test serums were heat inactivated at 56 C for 30 
minutes. Two-fold serial dilutions of the test serum (0.05 ml) were made 
in micro-titer plates using MEM as the diluent. Twenty to forty TCID50 
of virus in 0.05 ml of GBK cells suspended in MEM with 10% FCS, containing 
approximately 10,000 cells, were added to each well. Plates were incu-
bated at 37 C in a 5% incubator for 2 days. An inverted microscope3 was 
used to examine the plates for cytopathogenic effect (CPE). Neutraliza-
tion titers were ca 1cu1 a ted by the method of Spearman and Ka rber and re-
corded as the reciprocal of the dilution that produced a 50% endpoint (21). 
Plague reduction SN test 
Test serums were reheat inactivated at 56 C for 10 minutes. Two-fold 
serial dilutions were made in tubes using MEM without serum as the diluenL 
An equal volume of IBR virus calculated to contain 50 plaque-forming units 
(PFU) was added to each tube and the serum-virus mixtures were incubated 
at 37 C for 1 hour. Linbro 6-well tissue culture trays containing 48 hour 
monolayers of MDBK cells were used to titrate the virus. The medium was 
1Amicon Corp., Lexington, Mass. 
2Linbro Chemical Co., New Haven, Conn. 
3unitron Instrument Co . , Newton Highlands, Mass . 
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aspirated from the cultures and 0.5 ml of each virus-serum mixture were 
inoculated into two wells and incubated for 60 minutes at 37 C to allow 
the virus to adsorb to the cells. The inoculum was aspirated from the 
cells and the cells were overlaid with 0.5% Agarose1 and MEM with 2% FCS. 
Plates were incubated for 72 hours at 37 C. Cells were fixed in 10% 
fonnalin, the agar was removed and the cells stained with 1% crystal 
violet. The number of plaques were counted and titers were expressed as 
the reciprocal of the dilution that produced a 50% reduction in the number 
of plaques as compared to the number in the control cultures. 
Interferon assay 
Viral plaque reduction was used to measure interferon levels. Medium 
was aspirated from MDBK cell monolayers that had been grown in Linbro 6-
well tissue culture trays. Serial two-fold dilution of non-heat inacti-
vated serum were made in MEM and duplicate samples of each serum dilution 
(0.5 ml) were applied to the cell monolayer and incubated overnight . Con-
trol cultures were treated with negative serum . At the end of incubation, 
the serums were aspirated and the plates washed three times with R-saline. 
Vesicular stomatis virus (VSV) Indiana strain, calculated to contain 50 
PFU, was added to each well. Virus was adsorbed at 37 C for 1 hour, ex-
cess viral fluids were aspirated, and the cultures were overlaid with 0.5% 
Agarose in MEM containing 2% FCS. Plates were incubated for 48 hours and 
then fixed with 10% fonnalin. The agar was removed and the cells were 
stai ned with 1% crystal violet. Titers were calculated by the method 
stated in the plaque reduction test. 
1Marine Colloids, Inc., Rockland, Me. 
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Characterization of the bovine interferon 
Six criteri a were used to ascertain if the anti -viral inhibitor was 
interferon. Pool s of serums from each of two calves that had high inhibi-
tory titers were used for the characterization. After each treatment 
serums were compared in an assay with non-heat inactivated serum. 
1. Serums were heat inactivated at 56 C for 1 hour. 
2. Serums were placed in 3/8 inch dialysis tubing and dialyzed 
against Sorensen's (48) pH 7.4 for 24 hours at 4 C with two 
changes of buffer. The volume ratio of serum to buffer was 
1: 200. 
3. VSV and serum was mixed in equal volumes and allowed to neutral-
ize at room temperature for 1 hour. 
4. Serum was centrifuged in a Beckman L2-65B ultracentrifuge at 
100,000 g for 1 hour . 
5. Serums were adjusted to pH 2 with sterile 1 N HCl, held at that 
pH for 1 hour and then brought back to pH 7.4 with sterile 1 N 
NaOH. Volumes of serum, HCl and NaOH were carefully measured and 
the serum was adjusted with MEM to a 1 :2 dilution. 
6. Serums were applied to cell monolayers and incubated for 4 hours 
and compared with serums that had been applied to cell monolayers 
and incubated over night. 
Animal inoculation schedule 
Fifteen bull calves ranging in age from 6 weeks to 5 months were 
purchased from three local dairies and the Veterinary Medical Research 
Institute hereford herd. Calves were allowed to graze on pasture land 
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1 and were fed Calf Krunch . Three of the youngest calves were given a 
commercial milk replacer. 
Group ~ Vaccine DIV EMA 
Group A 
433 1 4 ml IM 
436 1 4 ml IM 
Group B 
435 1 4 ml IM 
14 2 ml IM 
6902 1 4 ml IM 
14 2 ml IM 
Group C 
434 1 4 ml IM 10/kg IV 
439 1 4 ml IM 1 O/kg IV 
Group D 
416 1 4 ml IM 
10 mg/kg IV 
14 2 ml IM 10 mg/kg IV 
426 l 4 ml IM 10 mg/kg IV 
14 2 ml IM 10 mg/kg IV 
Group E 
413 1 10 mg/kg IV 
428 10 mg/kg IV 
14 2 ml IM 10 mg/kg IV 
438 14 10 mg/kg IV 
l Calf Krunch-6101-27, Allied Mills , Chicago, Ill. 
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Group F 
445 28 10 mg/kg IV 




On day 30 all calves received 4 ml of t he Cooper challenge strain of 
IBR1 virus intranasally (IN) with a gas-powered atomizer using the me thod 
of Sinclair and Tamoglia (46}. 
Temperature and blood samples were taken daily for 5 days after each 
vaccination and weekly thereafter . Temperatures and blood samples were 
also collected daily for 5 days after challenge and on post-challenge (PC) 
days 7, 10 and 12. Blood samples were collected for serum and for total 
and differential white blood cell (WBC) counts. 
Temperatures of 102.7 F to 103.0 F were considered in the high-nonnal 
range. Those temperatures of 103.0 or higher were cons i dered above normal. 
Normal values for WBC counts range from 5,000 to 12,000 
Experiment II 
DIV EMA 
Solutions of DIVEMA were prepared the same as described in Experiment 
I. 
1veterinary Biologics Division, U.S.D.A., Ames, Ia. 
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Modified complement fixation test 
Microtiter adaptation of the complement fixation test as outlined by 
Casey (5) was used. Fresh bovine serum was added to the test system as 
described by Boulanger and Bannister (2). 
Complement fixation antigen 
An aliquot from the H. somnus challenge preparation was diluted 1 :500 
in phosphate buffered saline (PBS) (0.015 M) pH 7.2. One tenth ml of the 
1 :500 dilution was plated onto each of two chocolate agar plates (10). 
Plates were incubated at 37 C in a 5% co2 incubator for 24 hours. Colo-
nies were harvested by adding 4-5 ml PBS and gently scraping the colonies 
off the agar surface with a bent glass rod. This suspension was used to 
inoculate 30 plates. Inoculum, growth, and harvesting were the same as 
for the first two plates. The harvest was sedimented in an International 
centrifuge at 2,500 rpm for 15 minutes; The supernatant was decanted and 
the H. somnus resuspended in 50 ml of PBS. The bacteria were disrupted by 
sonic oscillation for 10 minutes in a Raytheon sonic oscillator, model OF 
101 1 to prepare antigen. 
Challenge agent 
H. somnus strain 12292 was passed two times in 7 day old embryonated 
eggs . The criterion for harvesting the yolk material was that the embryo 
die within 24 hours. The second passage of the micro-organisms was 
1Raytheon Industrial Operation, So. Norwalk, Conn. 
2R. E. Dierks, Veterinary Medical Research Institute, Iowa State 
University, Ames, Ia. 
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harvested, dispensed in 2 ml volumes and kept frozen at -70 C until used 
as challenge agent 1 week later. The inoculum contained 108 organisms per 
ml. 
Animal inoculation schedule 
Six calves were selected from animals which had been used in Experi-
ment I. Serums from the calves were tested by complement fixation and 
found negative for antibodies to H. somnus. Four of the calves (Groups 
and 2) had no previous exposure to DIVEMA and the calves in Group 3 had 
been given DIVEMA 80 days prior to this experiment. 
Calves were held in isolation units throughout the experiment and fed 
Wayne Calf Krunch and alfalfa hay. 
Group 1 (calves 433 and 436) each received 10 mg/kg of DIVEMA IV 48 
hours before challenge with ti:_ somnus. 
Group 2 (calves 435 and 6902) were given DIVEMA IV 8 hours after in-
fection which was at the first sign of a clinical illness. Both calves 
had temperatures of 104.0 F. 
Group 3 (calves 434 and 439) were control calves and received only 
the challenge agent. 
All six calves were injected intratracheally with 2 ml of ti:_ somnus 
organisms. Daily blood samples were collected for serum and for total and 
differential WBC counts. Rectal temperatures were taken at 8 hours post-
challenge and then every 24 hours. Calves were necropsied at death or 9 




Calves were inoculated according to the schedule as described in 
Materials and Methods. All of the calves were challenged on day 30 with 
a low passage Cooper strain of IBR virus. They were inoculated intra-
nasally using a gas-powered atomizer. All calves, except those in Group 
F, developed clinical signs of illness including fevers of 104.0 For 
higher, accelerated respiration rates, coughing, malaise, and conjuncti-
vitis. One control calf (calf 444) died on post-challenge (PC) day 2. 
The necropsy showed that the calf had a mild pneumonia and a small ce~vi­
cal abscess. The abscess was apparently due to infection in a wound suf-
fered when the animal was caught on the fence. 
Temperatures 
Temperatures of the calves in Group A are shown in Graph 1. The 
temperature of calf 433 remained normal throughout the vaccination period . 
Calf 436 had a rise in temperature on days 1 and 2 after vaccination, 
possibly a reaction to the vaccine. It also had a temperature rise on day 
25 that is unexplained . Both calves in this group had fevers from the IBR 
infection, beginning 48 hours after cha)lenge and remaining elevated for 5 
to 6 days. 
Temperatures of the calves in Group B are shown in Graph 2. The 
temperature of calf 434 was above normal on day 1. Calf 439 had a fever 
lasting from day 1 through day 3. The fever likely was a response to the 
DIVEMA or the vaccine. Calf 439 had unexplained above normal temperatures 
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from day 5 to day 12 and again on day 25. After challenge both animals 
had fevers, lasting from PC day 2 to PC day 4 and 5, as a result of the 
IBR infections. 
Temperatures of the calves in Group Care shown in Graph 3. The 
temperature of calf 435 remained normal throughout the pre-challenge 
period except for an elevation above normal on day 16 following the second 
dose of vaccine. Calf 6902 had a fever on day 2 and day 16 which may have 
been a reaction resulting from the vaccine. It had an unexplained fever 
on days 11 and 12 and also temperatures in the high nonnal range during 
the period following the second vaccination until 24 hours after challenge. 
Both calves developed post-challenge fevers as a result of the IBR infec-
tion. 
Temperatures of calves in Group D are shown in Graph 4. Calf 416 had 
a fever for 5 days after receiving the vaccine and DIVEMA. This calf's 
pre-challenge reaction was the most severe of all of the animals. It also 
had an increase in tempera ture on day 17, which was 3 days after the sec-
ond inoculation and again on day 25 . The temperature of calf 426 remained 
normal throughout the pre-challenge period except on day 25 . Both calves 
again developed fevers after challenge with IBR virus. 
Temperatures of calves in Group E are shown in Graph 5. Calf 428 
exhibited a temperature rise on day 14 an~ 15. The high-normal tempera-
ture on day 14 may have been caused by the calf being chased on a hot day. 
The fever on day 15 probably was due to the vaccine plus DIVEMA. Total 
WBC counts and differential staining tend to support this explanation. 
Calf 428 also had an unexplained fever on day 25. Calf 413 had a rise in 
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temperature above nonnal on days 1 and 2 after DIVEMA administration. On 
day 29 its temperature started to increase again and was high-normal on 
days 29 and 30. This rise in temperature is not explained . Its tempera-
ture rose to 103.6 F on PC day 1 and was above normal through PC day 6. 
Temperature of calf 438 remained normal through the pre-challenge period. 
All three calves developed fevers as a result of the IBR infection. 
Temperatures of calves in Group F are shown in Graph 6. Both calves 
in this group had temperatures that remained normal throughout the entire 
experiment. 
Group G temperatures are shown in Graph 7. Calf 444's temperature 
was normal both before and after challenge but the animal was found dead 
on PC day 2. The other control calf, no number, had a fever on day 29 but 
his temperature was high-normal on the day of challenge. No number had a 
fever from the IBR infection. 
Hematology 
WBC counts and differentials are shown in Tables 1-7. Almost all 
values are in the normal range, however, trends can be seen. Rises in 
WBCs occurred in every treatment group, but not every calf, at the be-
ginning of the vaccination period. This was presumably a response to the 
vaccine, DIVEMA, or both. An increase in WBCs also was observed during 
the middle of the pre-challenge period for at least one calf out of every 
group and may have been a response to the second dose of vaccine or DIVEMA. 
For those groups not receiving a second dose, as well as those that did, 
elevated WBCs may have been the result of the stress caused by moving the 
calves together into a single pen. The calves had been put together on 
day 12. 
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During the post-challenge period a slight leucopenia occurred for 
calves of all groups on PC day l followed by a return to slightly higher 
values on day 2. 
Serological studies 
Micro-titer serum neutralization tests were performed on all serums 
and the results are shown in Table 8. Calves in Groups A, Band D did not 
develop any detectable antibodies to IBR vaccine. Calves in Group D de-
veloped low transient titers. Calves in all groups except Group F de-
veloped post-challenge titers as though it was a primary response. 
To ascertain if the sensitivity of the neutralization tests could be 
improved plaque-reduction tests were done. It was felt that low titers 
might be detected more easily with this method and this procedure may also 
disaffirm or confirm the transient titers seen in Group C. 
The results of the plaque-reduction tests are shown in Table 9. Not 
all of the serums were retested. The differences found are noted in Table 
8. The only significant changes are found in Group F. Possible explana-
tions will be discussed later. 
Interferon assays 
The results of the interferon assay are shown in Table 10. The re-
sponses to the vaccine and DIVEMA were varied. Interferon was not de-
tected in the sera of calves in Group A after vaccination . A low level of 
interferon was detected for both calves in Group B after inoculation 
with vaccine and DIVEMA. For both calves in Group C detectable low levels 
of interferon occurred 2 and 3 days after the second dose of vaccine but 
not after the first dose. Calf 416 (Group D) had interferon levels in the 
serum throughout the experiment but had slightly higher levels after each 
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dose of vaccine and DIVEMA. Calf 426 (Group D) had low levels of inter-
feron on and following both vaccination days. For calf 428 (Group E) 
interferon production was detected with DIVEMA injection on days 4 and 5 
and also after vaccine and DIVEMA was given on days 16 and 18. Calf 413 
(Group E) had low level interferon titers throughout the experiment with 
no significant peaks during the pre-challenge period. Calf 438 (Group E) 
produced the highest pre-challenge titers of all the calves. On the third 
day after DIVEMA administration it developed a high serum level of inter-
feron which was still relatively high on the 7th and 11th days after the 
interferon first appeared. 
During the post-challenge period all calves produced interferon. 
Groups A, B, C, D and E peak levels of interferon are seen on PC days 3, 
4 and 5. Peak levels of interferon appeared on PC day 2 for Group F 
calves which had been given DIVEMA 48 hours before challenge. The serum 
levels of one control calf (no number) are not consistent with what one 
might expect to find in view of the findings of Group A through E. 
A summary of the characteristics of the bovine interferon measured in 
this assay can be found in Table 11. 
Experiment II 
Test animals were closely observed after administration of DIVEMA and 
after challenge with!!:._ somnus. Calves in Group l had been given DIVEMA 
48 hours before challenge. Calves in Group 2 were treated with DIVEMA 8 
hours after challenge when their temperatures had reached 104.0 F. Group 
3, the control group, received only the challenge agent. 
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Graph 8 shows the numbers of days each animal survived after chal-
lenge with!!.:_ somnus. As can be seen in the graph, DIVEMA given either 
before or after challenge did not protect against the lethal effects of 
the bacterial infection. Calf 6902 died 48 hours post challenge. Four of 
the five remaining calves started showing signs of a clinical illness 
typical of !!.:_ somnus infection on PC day 2. On the morning of PC day 3 
both calves in Group l and one control calf were dead . The condition of 
one of the two remaining calves, calf 435, progressively deteriorated and 
the animal was nearly dead when killed on PC day 9. Calf 434 recovered 
from the infection. 
Temperatures 
Graphs 9, 10 and 11 show temperature responses of each of the calves. 
Calves in all groups had temperatures of 104.0 For higher 8 hours after 
challenge. This was presumably a reaction to endotoxin that was in the 
inoculum. Temperatures of five of the six calves quickly returned to 
normal. The temperature of calf 6902 did not return to normal but instead 
rose to 104.8 Fat 24 hours post challenge. Four out of the five remain-
ing calves had fevers by PC 2. Control calf 434 1 s temperature remained 
normal throughout the course of its infection. 
Hematological studies 
Data collected from the hematological studies are shown in Tables 12, 
13 and 14. Group 1 calves had WBC counts in the high-normal range 24 
hours after administration of DIVEMA but the counts returned to pre-DIVEMA 
levels the day of challenge. The white count elevation was probably a 
response induced by DIVEMA. 
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A rise in WBCs occurred 8 hours after infection in calves of all 
three groups. The WBC counts ranged from 5,000 to 18,000 over the counts 
that had been obtained 8 hours earlier. In Group 1 calf 433's WBC count 
dropped at 24 hours post challenge and was increasing again when it died. 
The other calf in Group 1, calf 436, had a WBC count that remained above 
normal after challenge. For calves in Groups 2 and 3 there was a slight 
drop in WBCs at 24 hours but the numbers remained above normal. 
The differentials (Tables 12, 13 and 14) show that all calves had a 
PC left shift from approximately 80% lymphocytes down to 20%-50% lympho-
cytes. The calves in Group 1 had a 30% increase in neutrophil count 24 
hours after DIVEMA administration which had returned to normal by the time 
the animals were challenged. 
No distinctions based on the hematologic tests could be made between 
the groups that recei ved DIVEMA and the controls during the post-challenge 
period. 
Necropsy reports 
The two calves in Group 1 were found dead on the morning of PC 3. 
Both calves had a mild congestion in the dependent portion of the lung, 
petechial hemorrhage on the serosal surface of the heart, excess perito-
neal fluid, and a small abscess at the tracheal injection site. Calf 436, 
in addition, showed mild adhesions in the mesentery and an enteritis in 
the jejuneum. 
Calf 435 in Group 2 was nearly dead when he was killed for the post 
mortem examination. This calf was blind. The blindness was thought to be 
a recrudescence of the herpes infection. The necropsy revealed that it 
had pneumonia, petechial hemorrhage in the brain stem, mild adhesions in 
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the pericardium. Calf 6902 from Group 2 died on PC day 2. It had pneu-
monia in the dependent portion of the lung, meningeal congestion and a 
small abscess at the tracheal injection site. 
One control calf (calf 439) in Group 3 was found dead on PC day 3. 
The necropsy examination showed he had a small abscess at the injection 
site, moderate consolidation in the bottom half of the lung, petechial 
hemorrhage of the serosal surface of the heart, hemorrhage in the trachea 
and cervical lymph nodes, and an enteritis. The other control calf (calf 
434) had recovered from his infection when he was killed for the post 
mortem examination. The examination revealed a moderate pneumonia in the 
dependent cardiac lobe, adhesions in the pericardium, and moderate fibrin 
tags in the mesentery . 
There could be no distinctions made between those animals receiving 
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Table 1. WBC and differentials of Group A calvesa 
Calf 433 Calf 436 
Day WBC Bandsb Segsc Lymphsd WBC Bands Se gs Lymphs 
0 8,350 0 14 86 7,500 21 71 
l 8, 150 5 21 72 6,450 3 21 65 
2 9,700 10 18 66 6,500 2 14 81 
3 6,700 5 23 71 6,850 3 20 71 
4 6,250 3 28 69 4,800 3 21 74 
5 6,550 l 26 73 6,750 14 14 68 
11 7,950 5 22 68 7,050 0 27 69 
18 10, 500 13 16 71 6,200 16 12 67 
25 8,300 21 5 72 7,500 5 5 88 
29 7,500 7 16 78 6,300 l 15 84 
30e 7,900 5 18 77 7 'l 00 5 19 76 
l 6,800 6 21 72 6,300 8 16 76 
2 blood clotted 5,500 5 28 65 
3 8,900 15 23 61 8,240 19 33 46 
4 9,880 11 14 75 11,060 14 41 44 
5 8,000 12 17 71 6,400 9 21 69 
6 9, 110 7 23 67 7,300 9 10 79 
8 7,900 7 17 75 5, 100 2 11 81 
11 8,000 5,300 
13 5,500 5,300 




eDay cha 11 enged. 
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Table 2. WBC and differentials of Group B calvesa 
Calf 434 Calf 439 
Day WBC Bands0 Segsc Lymphsd WBC Bands Segs Lymphs 
0 9 ,400. l 21 86 8, l 00 2 35 62 
l 9,150 4 28 67 8,200 11 30 59 
2 9,800 3 6 81 5, l 00 10 21 68 
3 8,700 3 20 69 6,050 3 30 65 
4 a .• 600 2 17 76 5,900 2 14 84 
5 7,750 l 13 81 5,950 8 10 82 
11 7,000 3 13 8 6,650 2 16 74 
18 12,800 l . 3 93 6,700 12 5 79 
25 9,300 10 6 83 5,500 12 18 69. 
29 10,500 11 13 75 5,700 4 10 81 
30e 10,500 2 14 82 6, 100 2 20 75 
l 10·,500 7 23 65 .. 5, 700 9 25 63 
2 &,5oo 2. 22 65 5,700 3 31 64 
3 8,2QO. 9 21 61 7, ;mo 14 .34 52 
4 9,540 13 13 72 7,530 12 24 62 
5 8,000 7 18 73 . 5,400 7 12 Bo 
6 8,540 7 14 78 5,350 12 18 69 
8 7,300 l 10 87 4,300 3. 7 89 
11 7,500 4,200 
13 8,400 4,300 
aReceived one dose vaccine and one dose DIVEMA. 





Table 3. WBC and differentials of Group C calvesa 
Calf 435 Calf 6902 
Day WBC Bands6 Segsc Lymphsd WBC Bands Se gs Lymphs 
0 11'700 5 37 57 9,000 3 27 68 
1 10,500 13 21 65 7,450 1 35 60 
2 10,050 13 26 61 7,500 l 23 73 
3 8,800 5 35 51 
4 9,900 10 33 59 8,700 4 39 51 
5 l 0' 150 8 25 67 8,600 16 17 65 
11 11 ,450 3 32 60 10,500 0 14 82 
14 l 0,200 31 18 51 9,000 4 18 74 
15 11 ,600 28 12 57 11'500 4 36 54 
16 7,800 8 27 63 9,900 3 38 53 
17 6,800 9 29 60 7,300 9 31 59 
18 6,600 9 9 75 7,800 6 17 74 
25 9,800 11 12 73 7,700 5 4 87 
29 10,400 8 22 70 11 ,800 1 18 73 
30e 11,000 6 16 77 13,200 5 19 69 
1 8,900 4 35 69 11, 300 8 38 52 
2 7,900 6 42 51 9,900 19 35 46 
3 8,460 8 12 76 16, 600 13 44 42 
4 9,260 9 16 74 17, 700 16 17 67 
5 8,400 12 11 76 7, l 00 9 18 69 
6 8,900 7 11 81 9,090 7 15 70 
8 4,300 13 85 5,600 2 14 81 
11 7,300 7,200 
13 7,000 7, l 00 




eDay cha 11 enged. 
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Table 4. WBC and differentials of Group D calvesa 
Calf 416 Calf 426 
Day WBC Bands6 Segsc Lymphsd WBC Bands Segs Lymphs 
0 10,500 2 19 71 10 '150 l 15 84 
1 11'700 9 21 67 8,200 7 27 64 
2 8,800 7 36 55 8,200 6 16 78 
3 7,250 15 82 7,800 21 74 
4 6,700 7 91 7,800 21 75 
5 6,850 4 6 89 6,550 10 23 65 
11 7,500 11 87 9,000 l 11 88 
14 7,600 l 12 83 
15 9,000 5 8 87 11'700 23 20 56 
16 7,400 8 89 7,600 3 20 71 
17 6,400 15 85 6,000 1 21 76 
18 7,500 4 6 90 8,700 1 9 90 
25 5,500 6 11 83 6,900 5 17 76 
29 11 ,200 2 6 91 8,800 2 17 78 
30e 12 '700 100 16,700 6 12 81 
l 7,800 l 5 91 8,000 7 21 70 
2 8, 100 l 8 87 7,300 6 41 53 
3 6,290 11 5 82 11'100 11 38 50 
4 8,900 11 17 70 11 ,900 23 20 56 
5 7,300 3 12 84 8, l 00 8 19 67 
6 8,350 2 7 90 7,700 5 22 73 
8 6, l 00 2 4 92 6,300 l 3 95 
11 6,900 8,300 
13 7,300 8, l 00 




eDay cha 11 enged. 
Table 5 . ., . WBC and differenti a 1 s of Group E ~al vesa 
· Calf 428 Calf 412 Calf 438 
Day WBC. Bands b Segsc Lymphsd .WBC. ·Bands Segs Lymphs WBC Bands Segs Lymphs 
0 8,450 2 19 78 8,900 4 94 7,450 13 84 
1 7, l 00 7 19 74 10,400 12 26 62 6,550 4 29 61 
2 7,800 5 18 76 7,750 25 . 26 49 
3 8,000 28 70 10,700 15 82 
4 6,600 2 20 73 8,300 13 86 
5 5·, 150 6 16 72 8,
0
600 16 17 65 ..,, 
00 
11 5,650 4,900 2 97 
14 6,600 1 11 88 
15 9,250 24 22 54 il,000 22 35 43 
16 5,500 1 13 86 6,000 5 28 64 
17 5,400 1 10 88 5,600 1 15 84 
aCalves 428 and 413 received one dose DIVEMii.·on day 1. Calf 438 received one dose DIVEMA on 




Table 5. (continued) 
Calf 428 Calf 412 Calf 438 
Day WBC Bands Segs Lymphs WBC Bands Segs Lymphs WBC Bands Segs Lymphs 
18 9,700 12 85 8,700 28 14 57 10,400 16 12 67 
25 6,300 4 3 93 6,200 25 13 62 6, l 00 4 l 93 
29 8,320 l 3 95 9,720 7 25 66 6,600 5 8 85 
30 7,500 13 13 74 9,000 9 10 80 6,900 9 12 78 
l 5,600 10 87 8,300 3 22 71 6,200 l 19 77 
2 5,300 2 9 86 6,700 4 12 83 5,800 7 25 65 -+=>· 
lD 
3 7,220 7 21 72 7,000 9 24 65 8, 180 14 23 62 
4 7,900 7 14 77 10,400 28 13 60 10, 100 16 10 74 
5 7,700 10 18 69 6,500 1 19 77 7,400 13 13 74 
6 9,910 7 12 81 7,620 2 7 90 8,390 8 7 85 
8 5,500 2 7 88 4,500 6 3 89 5,000 2 8 87 
11 7' 100 6, 100 6, 100 
13 6,200 5,600 6,000 
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Table 6. WBC and differentials of Group F calvesa 
Calf 445 Calf 447 
Day WBC Bandsb Segsc Lymphsd WBC Bands Segs Lymphs 
28 7,550 4,950 
29 6,420 7 21 69 5,810 5 20 74 
3oe 6,800 8 20 70 5,700 7 38 54 
l 6,700 16 26 55 3,600 12 14 74 
2 6,900 15 26 57 12,200 l 13 85 
3 6,260 13 26 61 4,840 9 10 81 
4 9,400 30 18 52 5,800 13 28 58 
5 ·9,000 30 16 52 4,900 8 5 83 
6 7,920 7 32 59 5,900. 9 14 77 
8 3,.400 5 30 65 3,400 3 l 94 
11 4,900 3,200 
13. 5,000 ~ 3,200 






Table 7. WBC and differentials of Group G calvesa 
No number Calf 444 
Day WBC Bandsb Segsc Lymphsd WBC Bands Segs Lymphs 
29 13 ,400 7 18 70 6,420 12 26 59 
30e 14,400 13 33 54 6,900 21 26 53 
1 12,900 10 35 53 . 5, 600 23 53 24 
2 3 '100 9 16 71 Died 
3 11'900 7 27 65 
4 14,000 12 9 79 
5 10, 300 2 22 71 
6 10, 100 3 17 73 
8 6,900 6 7 87 
11 7,500 
13 7,800 





Table 8. Results of the micro-titer serum neutralization tests 
Group A B c D E F G 
No 
Day 433 436 434 439 435 6902 416 426 428 413 438 445 447 number 444 
0 0 0 0 0 0 0 0 0 0 0 0 a 
l 0 0 0 0 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 0 0 ,0 0 
3 0 0 0 0 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 0 0 0 0 
<J1 
5 0 0 0 0 0 0 0 0 0 0 0 N 
11 0 0 0 0 0 7 0 0 0 0 0 
14 0 0 0 0 5 4 0 0 0 0 0 
15 0 0 0 0 0 0 0 0 0 0 0 
16 0 0 0 0 7 0 0 0 0 0 0 
17 0 0 0 0 0 0 0 0 0 0 4b 
18 0 0 0 0 0 0 0 0 0 0 0 
25 0 0 0 0 0 0 0 0 0 0 0 oc oc 0 0 
28 QC oc 0 0 
a Not done. 
bTiters that were negative on plaque reduction. 
cTiters that were positive on plaque reduction. 
Table 8. (continued) 
Group A B c D E F G 
No 
Day 433 436 434 439 435 6902 416 426 428 413 438 445 447 number 444 
29 Q Q Q Q Q 0 0 Q 0 0 Q 6 17 Q Q 
3Qd Q 0 Q Q Q Q Q Q Q Q Q 5 oc Q 2b 
le Q 0 Q Q 5 0 6 2b Q 0 0 QC 10 Q died 
2 Q Q 0 Q Q Q Q Q Q 0 0 QC oc Q 
3 0 Q 0 6 0 Q 16 0 Q 5b Q 64 8 0 
U'1 
4 0 Q Q, 0 Q 3 0 0 0 0 0 32 8 0 w 
5 0 0 Q Q 0 3 0 0 0 0 0 38 8 5 
6 0 0 0 Q 0 3 0 0 0 0 0 45 7 0 
8 10 5 6 20 29 37 47 8 6 3 7 53 lQ 6 
11 128 76 54 219 128 >512 514 54 32 10 17 58 10 8 
13 151 130 3Q 153 219 >512 350 306 76 158 28 27 7 10 
dChallenged. 
ePost challenged. 
Table 9. Results of the plaque reduction serum neutralization tests 
Grou~ A B c D E F G 
No 
Day 433 436 434 439 435 6902 416 426 428 413 438 445 447 number 444 
0 0 0 0 0 0 0 0 0 a 0 
1 
2 0 0 0 
3 0 0 0 
4 0 0 0 
5 0 0 0 <.Tl ~ 
11 0 0 0 0 0 7 0 0 
14 4 4 0 
15 0 0 0 0 
16 2 0 0 
17 0 0 0 
18 0 0 0 0 
25 0 0 
28 32 8 
29 0 0 0 0 0 0 26 8 0 0 
30 0 0 0 30 11 0 0 
a Not done. 
Table 9. (continued) 
Group A B c D E F G 
No 
Day 433 436 434 439 435 6902 416 426 428 413 438 445 447 number 444 
lb 0 0 0 21 12 0 
2 0 8 0 0 0 0 0 >16 >16 0 
3 0 0 > 16 >16 
4 0 0 > 16 >16 
5 0 0 >16 >16 
6 0 0 
U1 
>16 >16 U1 
8 6 16 30 >16 
11 128 - >128 332 18 
13 >128 >128 >128 >128 >128 384 16 64 
bPost challenged. 
Table 10. Results of the interferon assay 
Graue A B c D E F G 
No 
Day 433 436 434 439 435 6902 416 426 428 413 438 445 447 number 444 
0 oa oa ob ob oa oa 15b 2b l 2c gC 22 NSd NS NS NS 
1 0 0 2 0 0 0 15 2 3 6 NS NS NS NS NS 
2 0 0 2 0 0 0 15 2 2 6 NS NS NS NS NS 
3 0 0 0 8 0 0 10 0 0 3 NS NS NS NS NS 
4 0 0 0 2 0 0 20 0 8 3 NS NS NS NS NS 
5 0 0 0 0 0 0 11 0 4 3 NS NS NS NS NS (.}1 ()) 
11 0 0 0 0 0 0 8 3 e 8 NS NS NS NS NS 
14 NS NS NS NS oa oa 4b 2b b NS NS NS NS NS NS 
15 NS NS NS NS 0 0 2 2 NS NSc NS NS NS NS 
16 NS NS NS NS 2 0 2 0 5 NS 0 NS NS NS NS 
17 NS NS NS NS 2 4 40 0 0 NS 0 NS NS NS NS 
aAdministered vaccine. 




Table 10 . (continued ) 
Group A B c D E F G 
No 
Day 433 436 434 439 435 6902 416 426 428 413 438 445 447 number 444 
18 0 2 0 0 4 8 11 0 3 8 35 NS NS NS NS 
25 0 2 0 0 11 0 2 2 0 9 35 NS NS NS NS 
28 NS NS NS NS NS NS NS NS NS NS NS 2c 2c 0 0 
29 0 0 0 0 8 3 0 2 0 8 20 0 0 0 0 
30f 0 0 0 2 7 2 0 0 0 6 3 4 0 2 0 
lg 01 0 0 0 4 7 2 0 2 0 6 2 10 4 16 Died -...J 
2 4 2 2 NS 8 11 7 4 6 14 7 68 85 14 
3 5 3 4 8 57 28 20 22 34 57 6 21 30 11 
4 11 6 8 14 38 28 24 16 40 57 34 21 26 2 
5 8 3 24 14 64 48 32 19 28 34 11 20 16 0 
6 6 3 16 11 32 34 30 10 16 21 6 0 9 0 
8 0 0 4 8 4 4 2 0 2 8 2 2 2 0 
13 0 0 4 3 2 2 2 NS 0 4 2 2 2 0 
f Challenged . 
9Post challenged. 
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Table 11 . Characterization of bovine serum interferon 
Procedure or criterion 
Dialysis 
Ultracentrifugation 
(100,000g for 1 hrs.) 
Acid treatment for 
l hr. at pH 2 
Shorten contact with 
cells (4 hours) 
Heat inactivation 
l hour 56 C 
Direct neutralization 























Loss of activity 
No reduction in virus 
plaque forming ability 
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Table 12. WBC and differentials of Group 1 calves 
Differential 
Neutrophils 
Day WBC Bands Segmented Lymphocytes 
Calf 433 
-2 6,6aa l 14 78 
-1 la,5aa 21 35 43 
aa 6' l aa 5 16 67 
ab 11 '1 aa 23 39 35 
1 7,7aa 18 35 45 
2 9,aaa 2a 37 4a 
3 Died 
Calf 436 
-2 7,aaa 1 13 79 
-1 12,4aa 13 26 57 
aa 6,5aa a 16 81 
ab 12,3aa 14 37 4a 
1 12,2aa la 33 49 
2 13,7aa 12 35 45 
3 Died 
a 8:3a AM. 
b 4:3a PM . 
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Table 13. WBC and differentials of Group 2 calves 
Differential 
Neutrophils 
Day WBC Bands Segmented Lymphocytes 
Calf 435 
-2 9,600 0 10 81 
-1 NDa 
ob 11'900 8 15 68 
oc 21,000 14 38 45 
1 15,300 19 23 55 
2 10, 900 18 22 54 
3 ND 
4 15,300 23 28 45 
9 Killed 
Calf 6902 
-2 13,600 2 13 78 
-1 ND 
ob 7,800 3 22 68 
oc 26'100 20 56 20 
1 24,600 10 33 49 
2 Died 
aNot done. 
b . 8.30 AM. 
c 4:30 PM. 
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Table 14. WBC and differentials of Group 3 calves 
Differential 
Neutrophils 
Day WBC Bands Segmented Lymphocytes 
Calf 434 
-2 12 ,900 l 11 80 
-1 NDa 
ob 13,900 4 8 79 
QC 19 'l 00 14 16 62 
l 17 ,200 8 33 49 
2 18' l 00 10 31 51 
3 ND 
4 15, 500 9 25 57 
9 Ki 11 ed 
Calf 439 
-2 8,600 15 81 
-1 ND 
ob 11 ,600 7 13 79 
QC 13, 300 7 59 33 
l 12,500 14 46 36 







The experiments were a preliminary investigation to examine the ef-
fectiveness of OIVEMA against both bacterial and viral agents and its en-
hancement of the irrmune response to a killed vaccine. Experiments in mice 
had shown that the multi-faceted mechanisms of action of DIVEMA could 
possibly enable this substance to be useful in combating the microorgan-
isms involved in the BRDC. 
There were two major aspects to Experiment I. The first was to de-
termine whether DIVEMA could enhance the inmune response to a killed virus 
vaccine and the second to see if DIVEMA alone could protect calves from 
IBR infection. 
A host's defense system against viruses is complicated. The type 
and degree of resistance depends upon the age, species, genetic makeup, 
state of health and immune status of the host as well as the virulence. 
size of the inoculum and portal of entry of the virus. Irrmune responses 
can be artificially divided into two groups, cell mediated responses and 
humoral responses; these two groups, however, are neither physiologically 
nor functionally mutually exclusive of each other. With many virus in-
fections, including herpes infection (24), cellular irrmunity is of partic-
ular importance. 
Cell mediated immune reactions may be responsible for most of the 
host's defense against IBR; however, humoral antibody levels are frequent-
ly measured to evaluate the host's immune status . I measured humeral 
antibody against IBR in this research as an indication of resistance to 
the agent. 
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Table 8 will show that the killed IBR vaccine, even though it con-
tained lo9·5TCI050 ,s before beta-propiolactone inactivation, did not pro-
vide protection for any of the calves either when given alone or when 
given with DIVEMA. Calves in Group C showed transient titers of neutral-
izing antibody and yet they were not protected. This could be because of 
a lack of antigenicity of the inactivated vaccine or the levels of specif-
ic viral antigens were too low to properly sensitize inmuno-competent 
cells . 
Since Braun et al. (3) reported DIVEMA enhanced specific responses of 
antibody formation, it was hoped that DIVEMA would present the killed 
antigen to the host's immune system in a manner that would mock the viral 
presentation of the successful modified-live vaccines. The vaccine was 
given IM and the DIVEMA IV. This was not a successful combination in 
activating the host's immune system as none of the calves in groups A-D 
were protected against the IN IBR challenge. Further studies should be 
made using different combinations of routes of administration of vaccine 
~nd DIVEMA. It would be advantageous to have a small laboratory animal as 
the host so that a variety of tests may be perfonned . 
At the time these experiments were conducted the effects of DIVEMA 
had not been measured in the calf. In human studies researchers reported 
toxic effects as indicated by elevated WBC counts and fever (29). Pigs 
receiving DIVEMA suffered adverse reactions, including abdominal pain and 
fevers. One pig died from a severe peritonitis that resulted from an IP 
injection of DIVEMA (23). 
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Calves from three herds were purchased and subsequently penned to-
gether. The animals developed fevers, diarrhea, and coughing during this 
initial holding period. Two calves died before the experiment was start-
ed; however, the other calves responded to antibiotic therapy. Attempts 
to iso late virus were negative. The cause of death was not determined. 
Because the calves had been ill, animals from the fourth herd were kept 
separate from the others until day 12 of the experiment. Calves in Groups 
F and G were the youngest animals in the experiment and were not purchased 
until 10 days before challenge. These calves came from the same herd as 
four others that had been purchased at the beginning of the experiment. 
Two days before challenge the calves were moved to a location several 
miles away where the live virus could be administered without danger of 
infecting other cattle at VMRI. Because the calves may have been stressed 
by the moves, change of environment, and change of diet, bacteria that 
would not ordinarily be expressed might be expressed. This could result 
in inapparent infections causing elevated WBCs, hence making interpreta-
tion of the data difficult. WBC counts and temperatures were used to 
evaluate the effects of DIVEMA in the calf host as well as the response of 
the calves to the vaccine. 
Some of the calves did have elevated WBCs and temperatures, as shown 
in Graphs 1-7 and Tables 1-7 that might be attributed to the DIVEMA. Calf 
416 was the only calf that had an adverse reaction. He had a very high 
temperature which lasted for 5 days. In addition the calf was lethargic 
and off feed. He had an interferon titer the day of vaccination which 
could suggest that there was a subclinical infection. One can not draw 
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any conclusions from one calf but it would be wise to check for toxic 
effects of DIVEMA in further studies. Except for calf 416 temperatures 
and WBCs were no higher in the calves receiving vaccine and DIVEMA and 
only DIVEMA than in the calves receiving only vaccine. 
The second aspect of Experiment I was to ascertain if DIVEMA would be 
effective in preventing viral infections in calves. DIVEMA had been ef-
fective in preventing a number of viral infections in mice (6,7,25,26,28, 
30,33,37). The mechanism of resistance has been suggested to be the pro-
duction of interferon. However, DIVEMA has been reported to protect 
against viral diseases for as long as 55 days (45), whi le interferon is 
short-lived. 
If we accept the fact that the vaccine used in Groups A-0 was not 
effective then we can look at these calves to evaluate the effectiveness 
of DIVEMA along with the calves in Groups E and F. DIVEMA given to calves 
in one or two doses 30 days or 14 days before challenge did not prevent 
infection by IBR virus. Any long term effectiveness that was hoped would 
prevail did not occur at the dosage given. 
Calves in Group F were given DIVEMA 48 hours before challenge. These 
were the only calves in this experiment that did not show any signs of a 
clinical infection. Unfortunately there is a problem of evaluating this 
data. Pre-purchase serums from the calves had been screened by the micro-
titer serum neutralization test and found to be negative for IBR anti-
bodies. In light of this the test results from the daily bleedings as 
shown in Table 8 are puzzling. Calf 445 had no detectable antibody to 
IBR 2 days pre-challenge but had measurable titers the day before chal-
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lenge and on the day of challenge. Calf 447 had no detectable titer 2 
days before challenge but had measurable titers 1 day before challenge and 
on PC day l. A plaque reduction test was conducted as it was thought this 
test would be more sensitive. The results of this showed all of the 
serums for these calves that were negative were now positive for IBR anti-
bodies. 
There are two ways in which the calves could have antibodies to IBR . 
They could have had a recent infection but this is doubtful in that the 
antibody pattern does not show a rise in titer that would reflect a recent 
infection. There is also a lack of any amnestic response after challenge 
that would be suggestive of a prior active infection. The calves came 
from the same herd that supplied me with six other calves which did not 
have antibodies against IBR and it seems unlikely that these two calves 
would be the only ones to get an IBR infection. 
The second possibility is that they had maternal antibodies and this 
appears to be the most likely explanation. Their antibody level remained 
low but steady during the post-challenge period . These calves were the 
youngest of the herd and were approximately 6-8 weeks old. If cell medi-
ated immunity is the key to recovery from a herpes infection as discussed 
earlier, then the maternal antibodies in the serum may not protect the 
calf from IBR virus. It is a possibility then that the administration of 
DIVEMA 48 hours pre-challenge was instrumental in prevention of the viral 
infection. This possibility can be resolved by further studies . 
Serum levels of interferon are frequently measured as an indication 
of anti-viral resistance an animal may have, even though interferon pro-
duction in the nasal cavity may be responsible for the host's defense . 
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The surrvnary of the results of the interferon assays as shown in Table 10 
show four items of interest. First there are low levels of interferon 
which appear 2 days after DIVEMA administration and reach peak levels at 
either 4 or 5 days . This was seen in approximately 50% of the calves that 
received DIVEMA. 
Second, there were five calves that had low interferon titers the day 
of challenge and yet they were not protected from infection. These low 
levels could have been induced as a result of the move to the new loca-
tion. 
Third, the IBR challenge virus produced higher titers than that in-
duced by DIVEMA. This is consistent with reports from other workers (26) 
that viral infections produce higher levels of interferon than do synthet-
ic interferon inducers. The interferon appeared at PC day 2 and reached 
peak levels at PC days 3, 4 and 5. Interferon was probably ultimately 
responsible for the calves' recovery . 
Fourth, the calves in Group F, which had been given DIVEMA 48 hours 
before challenge, had the highest titers of any of the groups. The peak 
levels of interferon were reached on PC day 2, which was the fourth day 
after administration of DIVEMA. It appears that the combination of stimu-
lation from the challenge and DIVEMA produced high titers. Whi le the 
possibility of antibodies providing the defense mechanism exists, as men-
tioned earlier, it is likely that interferon contributed to the protec-
tion. The serum levels of interferon were at their highest at the time 
the virus was probably multiplying rapidly in the host. 
If interferon induction is the mechanism of defense, further testing 
should be done to establish time intervals of effectiveness. Also one 
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could try intranasal administration of the DIVEMA. This route of induc-
tion would possibly eliminate some of the toxic side effects. 
If DIVEMA is to be effective against the micro-organisms of the BRDC 
it would necessarily have to be effective against many bacteria as well 
as many virus. DIVEMA has been reported to have antibacterial properties 
(27,35,41). 
In the second experiment DIVEMA's antibacterial properties were 
tested against a H. somnus infection. A review of Graph 8 shows that the 
DIVEMA treated calves did not survive the bacterial infection and further 
there was no sparing effects in the treated calves. Necropsies on the 
calves also revealed that there were no differences between the treated 
calves and the controls. 
An interesting response to the Hemophilus infection, which has not 
been reported for experimentally infected calves, was the sharp rise is 
temperature and WBCs hours after infections. Temperatures and WBCs then 
subsided and were found to be normal 24 hours after infection. This re-
action is not consistent with an endotoxin response in that the WBC count 
rose rather than having an immediate drop. The most logical explanation 
is a rapidly disseminating bacterial infection unless DIVEMA alters the 
reaction normally observed with an endotoxin . 
Calf 6902's temperature and WBC did not return to normal but con-
tinued to rise and the animal died 24 hours before the calves in Group l 
and one control calf (as shown in Graph 8). The possibility exists that 
there was an adverse reaction from the DIVEMA that hastened its death. 
Munson and Regelson (31) reported that DIVEMA produces a sensitization to 
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endotoxin. Their experiments show that the amount of endotoxin required 
to produce lethal effects is 300 times less in the DIVEMA treated mice 
than in nontreated animals. Calf 435 was also treated with DIVEMA 8 
hours after infection. It was almost dead when it was killed on the 9th 
day after infection. One could surmise that DIVEMA may have prolonged its 
life since it lived longer than the others except for one control. Con-
trol calf 434 which was the only one to recover from the infection and 
calf 435 came from the same herd and were the oldest calves and the only 
two Jerseys in this study. Age and genetic factors could have made them 
more resistant to the infection and perhaps calf 435 would have recovered 
had it not received DIVEMA. 
The possibilities discussed in the preceding paragraph can at best be 
only conjectures. The small number of calves used in this study do not 
allow one to draw conclusions except that the calves treated with DIVEMA 
as outlined in Materials and Methods did not confer resistance to H. 
somnus infection. 
It is doubtful that DIVEMA can be used in the treatment or in pre-
vention of cattle suffering from respiratory diseases. It had been hoped 
the diverse mechanisms of action of DIVEMA could protect the calves from 
the many micro -organisms that makeup the BRDC. Unfortunately this di-
versity also works against the usefulness of DIVEMA. Whether a host 
treated with DIVEMA had decreased or increased resistance to infection de-
pends on a number of factors such as route of administration, time inter-
val between treatment and infection and pathogenesis of the infection. 
DIVEMA did not enhance the immune response to the killed IBR vaccine and 
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did not confer any resistance to !h_ somnus infection; however, there is 
some evidence to suggest that DIVEMA when administered 2 days before chal-
lenge protected the calves against IBR infection. 
In conclusion DIVEMA did not provide any protection against bacterial 
challenge of cal ves in the H. somnus study . Additional work must be com-
pleted to determine the role of this compound in the protection of cattle 
against specific viral infections. 
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